Advocacy intelligence hub — real-time data for patient organizations
Tukysa: FDA approved
in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Tukysa
(tucatinib)Orphan drugSeagen Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in...
Erbitux
(cetuximab)Orphan drugstandardImClone Systems Incorporated
Epidermal Growth Factor Receptor Antagonist [EPC]
12.1 Mechanism of Action The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane glycoprotein that is a member of a subfamily o...
View all NON RARE IN EUROPE: Colorectal cancer specialists →